drugset / Trial / NCT04575896

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896

Phase 4 Completed 10 enrolled Johns Hopkins University
NaSingle-groupOpen-labelTreatment

Summary

In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 2 weeks post-renal transplant.

Timeline

Start
2020-11-20
Primary completion
2023-11-28
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject glecaprevir Other / unclassified 300 mg Oral
Subject pibrentasvir Other / unclassified 120 mg Oral